Sarah Hendrickx Selected Research

miltefosine (Impavido)

1/2021	Miltefosine enhances infectivity of a miltefosine-resistant Leishmania infantum strain by attenuating its innate immune recognition.
2/2020	Phenotypic adaptations of Leishmania donovani to recurrent miltefosine exposure and impact on sand fly infection.
1/2020	Comparative evaluation of nucleic acid stabilizing reagents for RNA- and DNA-based Leishmania detection in blood as proxy for visceral burdens.
1/2020	Impact of clinically acquired miltefosine resistance by Leishmania infantum on mouse and sand fly infection.
12/2019	Impaired development of a miltefosine-resistant Leishmania infantum strain in the sand fly vectors Phlebotomus perniciosus and Lutzomyia longipalpis.
1/2019	Miltefosine enhances the fitness of a non-virulent drug-resistant Leishmania infantum strain.
1/2018	Miltefosine-resistant Leishmania infantum strains with an impaired MT/ROS3 transporter complex retain amphotericin B susceptibility.
5/2017	Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
10/2016	Molecular detection of infection homogeneity and impact of miltefosine treatment in a Syrian golden hamster model of Leishmania donovani and L. infantum visceral leishmaniasis.
1/2016	Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sarah Hendrickx Research Topics

Disease

14	Visceral Leishmaniasis (Kala Azar) 01/2022 - 01/2012
13	Infections 01/2021 - 09/2012
5	Leishmaniasis 01/2022 - 10/2018
2	Cutaneous Leishmaniasis 10/2020 - 02/2011
2	Parasitic Diseases (Parasitic Disease) 10/2019 - 09/2016
1	Persistent Infection 01/2022
1	Trypanosomiasis 01/2022
1	Candidiasis (Moniliasis) 10/2020
1	Virus Diseases (Viral Diseases) 01/2020
1	Out-of-Hospital Cardiac Arrest 10/2019
1	Drug-Related Side Effects and Adverse Reactions 10/2019
1	Body Weight (Weight, Body) 02/2011

Drug/Important Bio-Agent (IBA)

11	miltefosine (Impavido)IBA 01/2021 - 11/2012
9	Pharmaceutical PreparationsIBA 01/2022 - 09/2016
6	N(1)-methyl-2-lysergic acid diethylamide (MIL)IBA 01/2021 - 01/2016
3	Paromomycin (Paromomycin Sulfate)FDA LinkGeneric 07/2021 - 01/2012
2	liposomal amphotericin B FDA Link 01/2018 - 05/2017
2	oleylphosphocholineIBA 01/2016 - 11/2012
1	NucleosidesIBA 01/2022
1	Firefly LuciferasesIBA 01/2021
1	Red Fluorescent ProteinIBA 01/2021
1	fluorescent protein 583IBA 01/2021
1	LipidsIBA 10/2020
1	Interferon-alpha (Interferon Alfa)IBA 01/2020
1	Indicators and Reagents (Reagents)IBA 01/2020
1	Interferon Type IIBA 01/2020
1	Sialic Acid Binding Ig-like Lectin 1IBA 01/2020
1	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2018
1	CytokinesIBA 11/2018
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 11/2018
1	Dihydrotachysterol (AT 10)IBA 01/2016
1	PhosphatidylserinesIBA 09/2012
1	PX-6518IBA 02/2011
1	Antimony Sodium Gluconate (Sodium, Stibogluconate)IBA 02/2011

Therapy/Procedure

3	Therapeutics 02/2020 - 01/2018
1	Cardiopulmonary Resuscitation (CPR) 10/2019
1	Drug Therapy (Chemotherapy) 10/2016